Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Functional microRNA binding site variants.

Yuan Y, Weidhaas JB.

Mol Oncol. 2019 Jan;13(1):4-8. doi: 10.1002/1878-0261.12421. Epub 2018 Dec 26. Review.

2.

MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.

Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES.

Hum Pathol. 2018 Jun;76:133-140. doi: 10.1016/j.humpath.2018.02.019. Epub 2018 Mar 5.

PMID:
29518404
3.

The patient's perspective on breast radiotherapy: Initial fears and expectations versus reality.

Shaverdian N, Wang X, Hegde JV, Aledia C, Weidhaas JB, Steinberg ML, McCloskey SA.

Cancer. 2018 Apr 15;124(8):1673-1681. doi: 10.1002/cncr.31159. Epub 2018 Feb 26.

PMID:
29479673
4.

Assessing the Effect of Lifetime Contralateral Breast Cancer Risk on the Selection of Contralateral Prophylactic Mastectomy for Unilateral Breast Cancer.

Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA.

Clin Breast Cancer. 2018 Apr;18(2):e205-e218. doi: 10.1016/j.clbc.2017.09.010. Epub 2017 Sep 27.

PMID:
29050918
5.

Predictors associated with MRI surveillance screening in women with a personal history of unilateral breast cancer but without a genetic predisposition for future contralateral breast cancer.

Hegde JV, Wang X, Attai DJ, DiNome ML, Kusske A, Hoyt AC, Hurvitz SA, Weidhaas JB, Steinberg ML, McCloskey SA.

Breast Cancer Res Treat. 2017 Nov;166(1):145-156. doi: 10.1007/s10549-017-4392-4. Epub 2017 Jul 12.

PMID:
28702891
6.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH.

JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478.

7.

Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein.

Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas JB, Tuck DP, Sweasy JB.

Mol Cancer Res. 2016 Nov;14(11):1068-1077. Epub 2016 Sep 12.

8.

Erratum: The Non-Coding RNA Journal Club: Highlights on Recent Papers-4. Non-Coding RNA 2016, 2, 9.

Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB.

Noncoding RNA. 2016 Sep 30;2(4). pii: E10. doi: 10.3390/ncrna2040010.

9.

The Non-Coding RNA Journal Club: Highlights on Recent Papers-4.

Gautheret D, Taube JH, Mani SA, Santulli G, Cuerda-Gil D, Slotkin RK, Zhang B, Wang Y, Salzman DW, Weidhaas JB.

Noncoding RNA. 2016 Sep 21;2(3). pii: E9. doi: 10.3390/ncrna2030009.

10.

miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage.

Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB.

Nat Commun. 2016 Mar 21;7:10954. doi: 10.1038/ncomms10954.

11.

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.

McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB.

Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11.

12.

Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase.

Chen J, Morrical MD, Donigan KA, Weidhaas JB, Sweasy JB, Averill AM, Tomczak JA, Morrical SW.

Nucleic Acids Res. 2015 Jan;43(2):1098-111. doi: 10.1093/nar/gku1337. Epub 2014 Dec 24.

13.

A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA.

Nath SK, Chen ZJ, Rowe BP, Blitzblau RC, Aneja S, Grube BJ, Horowitz NR, Weidhaas JB.

J Radiat Oncol. 2014 Dec;3(4):371-378.

14.

A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.

Saridaki Z, Weidhaas JB, Lenz HJ, Laurent-Puig P, Jacobs B, De Schutter J, De Roock W, Salzman DW, Zhang W, Yang D, Pilati C, Bouché O, Piessevaux H, Tejpar S.

Clin Cancer Res. 2014 Sep 1;20(17):4499-4510. doi: 10.1158/1078-0432.CCR-14-0348.

15.

A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer.

Dorairaj JJ, Salzman DW, Wall D, Rounds T, Preskill C, Sullivan CA, Lindner R, Curran C, Lezon-Geyda K, McVeigh T, Harris L, Newell J, Kerin MJ, Wood M, Miller N, Weidhaas JB.

BMC Cancer. 2014 Jun 10;14:421. doi: 10.1186/1471-2407-14-421.

16.

Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.

Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ.

Cell Cycle. 2014;13(6):1030-40. doi: 10.4161/cc.27941. Epub 2014 Feb 3.

17.

Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary.

Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):11-7. doi: 10.1016/j.ijrobp.2013.09.040. Epub 2013 Nov 15. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1115.

PMID:
24246724
18.

SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers.

Preskill C, Weidhaas JB.

Crit Rev Oncog. 2013;18(4):327-40. Review.

19.

Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.

Kunos CA, Winter K, Dicker AP, Small W Jr, Abdul-Karim FW, Dawson D, Jhingran A, Valicenti R, Weidhaas JB, Gaffney DK.

Int J Gynecol Cancer. 2013 May;23(4):615-21. doi: 10.1097/IGC.0b013e31828b4eb5.

20.

COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib: a quantitative immunohistochemical analysis of RTOG C0128.

Doll CM, Winter K, Gaffney DK, Ryu JK, Jhingran A, Dicker AP, Weidhaas JB, Miller BE, Magliocco AM.

Int J Gynecol Cancer. 2013 Jan;23(1):176-83. doi: 10.1097/IGC.0b013e3182791efc.

Supplemental Content

Loading ...
Support Center